All In Biotech

NDA 020955 · Sanofi Aventis US

Ferrlecit

Sodium Ferric Gluconate Complex · Injection · Parenteral Iron Replacement

NovelPriority review

Last checked: Nov 20, 2026Latest source record: Mar 16, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1999

Feb 18, 1999

Approved uses

3

Original approval plus efficacy supplements

Registered trials

12

3 Phase 3, 0 recruiting

FAERS reports

2,174

1,765 serious, 449 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 7, 2025.

Ferrlecit is indicated for the treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. Ferrlecit is an iron replacement product for treatment of iron deficiency anemia in adult patients and in pediatric patients age 6 years and older with chronic kidney disease receiving hemodialysis who are receiving supplemental epoetin therapy. ( 1 )

Mechanism: Ferrlecit is used to replete the body content of iron. Iron is critical for normal hemoglobin synthesis to maintain oxygen transport. Additionally, iron is necessary for metabolism and various enzymatic processes.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • FERRLECIT · SODIUM FERRIC GLUCONATE COMPLEX EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML) · INJECTABLE, INJECTION · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Ferric Gluconate Complex" as an intervention, any sponsor and status, largest first.

All 12 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • nausea519
  • vomiting463
  • abdominal pain415
  • dyspnoea397
  • sepsis301
  • general physical health deterioration293
  • abdominal distension278
  • off label use277
  • hyponatraemia268
  • ascites267
  • multiple organ dysfunction syndrome265
  • appendicitis263

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200461
200555
200671
200748
200857
200997
201073
201182
201276
201370
201481
201583
201667
201768
201848
201993
2020128
2021174
2022120
2023175
2024218
2025138
202691

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Ferrlecit* (Sodium Ferric Gluconat/Sucrose*) · HCPCS J2916

2024 spending

$250K

Beneficiaries

2,233

12,783 claims

Per beneficiary

$112

2024 ASP limit $2.22 per unit

View as table
YearSpending
2020$295,322
2021$259,492
2022$229,902
2023$251,052
2024$250,133

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 24 on PubMed

Sponsor: Sanofi

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.